FDA Warning Letters in the HCT/P Sector

The U.S. Food and Drug Administration periodically issues warning letters to organizations when the agency believes that activities may fall outside applicable regulatory requirements governing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).

These communications are part of the FDA’s broader regulatory oversight framework established under 21 CFR Part 1271.

Purpose of FDA Warning Letters

FDA warning letters are formal communications issued to notify organizations of regulatory concerns identified during inspections, investigations, or regulatory review.

• Identification of potential regulatory violations
• Opportunity for corrective action
• Documentation of enforcement oversight

These communications may involve concerns related to regulatory classification, manufacturing practices, or marketing activities associated with certain biological materials.

Regulatory Context

Warning letters related to HCT/P regulation frequently involve interpretation of criteria defined in 21 CFR 1271.10(a).

Further explanation is available in the Section 361 vs Section 351 regulatory overview.

Common Regulatory Issues Identified

• Product classification considerations
• Manufacturing safeguards and compliance controls
• Marketing or labeling communications
• Documentation of donor eligibility determination

More detail is available in the Current Good Tissue Practice (cGTP) overview.

Regulatory Awareness

Reviewing public enforcement communications may help organizations better understand regulatory interpretation and compliance expectations.

Additional discussion is available in the FDA Enforcement Landscape overview.

This information is for educational purposes only. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. For use by licensed healthcare professionals.